The UK company expects the pyrophosphorolysis-based technology to have cost and convenience advantages over sequencing-based assays.
The company plans to launch an early access program for its DefineMBC assay in April, followed by a full commercial launch later in the year.
Companies are entering the human reproduction field with embryo tests claiming to help minimize genetic risk for a host of complex diseases.
The company is planning to increase the throughput of and applications for the Alto instrument, while expanding its reach into the UK and Asia Pacific.
The company now plans to establish a CLIA laboratory and to launch a roughly 500-person study in cancer patients, in support of obtaining FDA clearance.
The Mount Sinai School of Medicine spinout plans to help diagnose autism spectrum disorders earlier by evaluating individuals' past environmental exposures.
After a promising pilot study, researchers at the University of Helsinki are starting a larger investigation of patients' response to drugs selected via this method.
The minimally invasive focused ultrasound technique temporarily permeabilizes the blood-brain barrier, facilitating the passage of ctDNA into the bloodstream.
Proceeds from a recent European public offering will fund commercialization of the French company's Ikoniscope20 platform in the US and EU.
Sysmex also recently formed a companion diagnostic development partnership with Qiagen, which could help with its efforts in this area.